Harmony Biosciences Holdings (HRMY) Free Cash Flow (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Free Cash Flow data on file, last reported at $27.8 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 18.01% year-over-year to $27.8 million; the trailing twelve-month figure through Mar 2026 stood at $341.8 million (up 54.38% YoY), and the FY2025 full-year result was $347.9 million, up 59.09% from the prior year.
• Free Cash Flow declined to $27.8 million in Q1 2026, from $126.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $126.0 million in Q4 2025 to a low of $26.7 million in Q4 2022.
• A 5-year average of $56.3 million and a median of $42.6 million in 2023 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow retreated 28.92% in 2022 and soared 186.97% in 2023, its largest moves.
• Tracing HRMY's Free Cash Flow over 5 years: stood at $26.7 million in 2022, then soared by 186.97% to $76.6 million in 2023, then decreased by 1.97% to $75.0 million in 2024, then surged by 67.95% to $126.0 million in 2025, then plunged by 77.98% to $27.8 million in 2026.
• Business Quant data shows HRMY's Free Cash Flow at $27.8 million in Q1 2026, $126.0 million in Q4 2025, and $108.7 million in Q3 2025.